LESLIE FINCH: Open Payments
NPI 1033863634 · DRESDEN, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,122 in 121 payments from 12 companies in 2025. Trend: 2023 $1,081 · 2024 $1,524 · 2025 $2,122
Food & beverage: $2,116Education: $5
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 18 | $333 |
| Alkermes, Inc. | 14 | $322 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 19 | $292 |
| Janssen Pharmaceuticals, Inc | 11 | $219 |
| Vanda Pharmaceuticals Inc. | 7 | $205 |
| ABBVIE INC. | 15 | $171 |
| Axsome Therapeutics, Inc. | 10 | $169 |
| Otsuka America Pharmaceutical, Inc. | 15 | $165 |
| Lundbeck LLC | 6 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $54 |
Products named: INGREZZA, ARISTADA, CAPLYTA, INVEGA SUSTENNA, HETLIOZ, VRAYLAR, Auvelity, REXULTI.
Industry payments across TN — which companies pay providers there.
